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Bedaquiline (BDQ), an inhibitor of the mycobacterial F1Fo-ATP syn-
thase, has revolutionized the antitubercular drug discovery pro-
gram by defining energy metabolism as a potent new target
space. Several studies have recently suggested that BDQ ulti-
mately causes mycobacterial cell death through a phenomenon
known as uncoupling. The biochemical basis underlying this, in
BDQ, is unresolved and may represent a new pathway to the de-
velopment of effective therapeutics. In this communication, we
demonstrate that BDQ can inhibit ATP synthesis in Escherichia coli
by functioning as a H+/K+ ionophore, causing transmembrane pH
and potassium gradients to be equilibrated. Despite the apparent
lack of a BDQ-binding site, incorporating the E. coli Fo subunit into
liposomes enhanced the ionophoric activity of BDQ. We discuss
the possibility that localization of BDQ at F1Fo-ATP synthases en-
ables BDQ to create an uncoupled microenvironment, by antiport-
ing H+/K+. Ionophoric properties may be desirable in high-affinity
antimicrobials targeting integral membrane proteins.
bedaquiline | tuberculosis | respiration | uncoupler | ionophore
The paucity of new drug leads developed through target-basedscreening since 1999, compared with phenotypic screening,
has largely been attributed to poorly resolved modes of action
(1). Furthermore, compounds with new molecular effects are
discovered through phenotypic screening methods, and the anti-
tubercular medicine bedaquiline (BDQ, Sirturo), FDA approved
in December 2012, is no exception (2, 3). An inhibitor of the
mycobacterial F1Fo-ATP synthase (henceforth F1Fo), BDQ dem-
onstrates that metabolism and energy generation is a promising
new target space. However, despite only 5 y of clinical use, re-
sistance in both laboratory and clinical settings has been reported
(4–6), reinforcing the need to mine this new target space for
second-generation compounds. However, this process will be
slowed without thoroughly resolving the mode of action of first-
generation inhibitors. Important aspects of BDQ’s mode of action
are unresolved, including the time-dependent mechanism of killing
and the molecular basis for selectivity between bacterial strains.
BDQ has been demonstrated to bind to the c-ring rotor of the
Fo portion of the mycobacterial ATP synthase (7, 8); concomi-
tantly the synthesis of ATP, an essential energy currency in bi-
ology, is inhibited and intracellular ATP levels drop (7, 9). BDQ is
not reported to inhibit growth of nonmycobacterial strains (2) and
in mammalian mitochondria the drug did not affect either ATP
synthesis activity (10) or the membrane potential (11). Inhibition
of mycobacterial growth by BDQ can be attributed to stereospe-
cific inhibition of ATP synthase (7) leading to a decrease in in-
tracellular ATP content (9, 12). The bactericidal activity and time-
dependent killing of Mycobacterium tuberculosis by BDQ, on the
other hand, is less well resolved. BDQ concentrations several or-
ders of magnitude higher than that required for inhibition of
growth are required for bactericidal activity (12, 13). It has also
been demonstrated that BDQ stimulates oxygen consumption in
Mycobacterium smegmatis (13) and M. tuberculosis (14). From
these studies it has been proposed that BDQ is an uncoupler of
respiration and ATP synthesis (11, 13), collapsing the trans-
membrane pH gradient component of the proton motive force
(PMF) ultimately leading to cell death (13).
The PMF is an electrochemical gradient consisting of both a
transmembrane pH gradient (acidoutside/alkalineinside) and the
membrane potential (ΔpH and Δψ, respectively), which is most
well known for its utilization by the F1Fo synthase during ATP
synthesis. Protonophores and ionophores are membrane diffusible
chemicals that can bind and transport protons or other cations and
can act to equilibrate/dissipate these gradients (15, 16). The cel-
lular response to these chemicals is to increase respiration in an
attempt to maintain the PMF, resulting in futile cycling of ions that
is uncoupled from ATP synthesis, also known as “uncoupling.”
Protonophores generally are lipophilic weak acids, such as
carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP)
or carbonyl cyanide 3-chlorophenylhydrazone (CCCP) (17),
which carry both protons and charge by directly binding and
shuttling protons across the cell membrane. Extensive de-
localization of the negative charge allows the deprotonated form
to cross the lipid bilayer. Although less well characterized, cat-
ionic protonophores have been reported (18–20). These mole-
cules are lipophilic weak bases, as opposed to weak acids, and
delocalize a positive charge by similar mechanisms. Carrying
protons without simultaneously moving a compensatory ion
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collapses both the ΔpH and Δψ (15). Ionophores are instead
capable of binding and shuttling larger ions, sometimes in ad-
dition to protons. Nigericin is an example of a molecule that
carries both cations and protons (15), by binding said ions
through its carboxylate moiety. Nigericin antiports K+ and H+,
an electroneutral exchange, to collapse only the ΔpH. Valino-
mycin instead carries only larger cations, not protons, and so
collapses the Δψ while maintaining the ΔpH (15). BDQ has been
proposed to function as a cationic protonophore (11). However,
this result does not explain the observation that BDQ collapses
only the ΔpH, but not the Δψ in M. smegmatis membrane vesi-
cles and the dependence on ATP synthase binding (13). The
counter ion, and the mechanism by which the counter ion is
moved to maintain electroneutrality, is unresolved. Whether
BDQ is a protono-/ionophore in its own right, requires the
presence of an ATP synthase for its activity, or both, is unknown.
In this communication we report that BDQ inhibits ATP syn-
thesis in Escherichia coli, an organism reported to resist BDQ
growth inhibition, by dissipating the PMF. E. coli is a useful model
organism due to the ease and high yield of F1Fo purification, the
bidirectional nature of the enzyme’s activity (in contrast to the
mycobacterial variant) (21), and the ability to separate the enzyme
into its F1 and Fo subcomplexes for focused analysis. The E. coli
F1Fo is not essential, unlike in mycobacteria (22), and so gene
deletions are readily available (23). Further analysis in lipid vesicles
demonstrates that BDQ can function as a cationic protonophore;
but the addition of opposing salt gradients enhances this activity,
suggesting BDQ is in fact a bona fide H+/K+ ionophore. The E. coli
ATP synthase Fo subunit enhanced this activity, although dispens-
able, suggesting BDQ accumulates at an unresolved binding site.
These activities occur at BDQ concentrations comparable to that
required for bactericidal activity (cell killing) (12, 13), and therefore
we invoke our model to provide a potential explanation for pre-
liminary observations linking the stimulation of oxygen consump-
tion to mycobacterial cell death (11, 13, 14). Combining an
ionophoric moiety with a potent membrane protein-binding moiety
may therefore be desirable in future antibiotic development.
Results
BDQ Inhibits ATP Synthesis in E. coli by Ionophoric Uncoupling. The
cause of mycobacterial cell death upon bedaquiline addition is
unclear, although several studies have implicated respiratory
uncoupling (11, 13, 14). A correlation between uncoupling in
E. coli andM. smegmatismembranes was previously observed (11),
but the molecular mechanism is poorly resolved and hence the
focus of our current study. The minimum inhibitory concentration
(MIC) of BDQ against E. coli is reported to be >32 μg·mL−1
(58 μM) (2). In our own experiments we similarly found no
growth inhibition for E. coli MG1655 (wild-type), testing up to
100 μM BDQ. In contrast to its lack of growth inhibition and
consistent with previous reports (11), we found that BDQ could
dissipate a ΔpH in inverted membrane vesicles (IMVs) (Fig. 1A)
of E. coli that were energized by either NADH oxidation or ATP
hydrolysis (Fig. 1B and SI Appendix, Fig. S2). Extending this
finding, we found that BDQ was able to dissipate the ΔpH in
IMVs of either E. coli with a deletion in the F1Fo operon (Fig. 1B)
or the same strain overexpressing F1Fo (Fig. 1B). Expression was
confirmed by activity and Western blots (SI Appendix, Fig. S3).
The PMF is obligatory for ATP synthesis, but ATP hydrolysis is
not a PMF-consuming process and can proceed in its absence (24).
Consistently, BDQ was able to inhibit ATP synthesis in E. coli
IMVs at concentrations similar to that causing ΔpH dissipation
(Fig. 1C), with an inhibitory concentration for 50% of the response
(IC50) of ∼5 μM. ATP hydrolysis was unaffected by the addition of
BDQ, but strongly inhibited by the Fo inhibitor N,N′-dicyclohex-
ylcarbodiimide (DCCD) (Fig. 1D). This suggests that BDQ is
causing uncoupling by directly binding and shuttling protons
(protonophore or ionophore) to collapse the ΔpH gradient.
Nigericin was sufficient to inhibit ATP synthesis in our membrane
preparations (SI Appendix, Fig. S4), suggesting our preparations
produced a PMF composed mainly of a ΔpH. Acridine orange
(ΔpH probe) and oxonol quenching (Δψ probe) profiles (SI Ap-
pendix, Figs. S5 and S6) suggest that valinomycin and nigericin are
working as intended in our assay conditions, only uncoupling their
respective component of the PMF, while the pore-forming gram-
icidin can completely equilibrate the entire PMF (SI Appendix, Fig.
S6 A and B). Therefore, ATP synthesis results from this assay
system may not inform on the role of the membrane potential. To
address this, we performed oxonol quenching assays and found
that BDQ does not collapse the Δψ in IMVs (SI Appendix, Fig. S6
E and F). This is similar to previous observations in M. smegmatis
(13). The residual ATP synthesis activity (∼30%) in BDQ-treated
IMVs (Fig. 1C) may represent Δψ-driven ATP synthesis.
To confirm that some unspecified membrane protein (for ex-
ample, H+-driven antiporters or efflux pumps) does not move
ions in response to BDQ, we reconstituted the purified E. coli
F1Fo (SI Appendix, Fig. S7) into proteoliposomes (Fig. 2A) and
assessed the effects of BDQ in this system. BDQ could collapse a
ΔpH gradient generated by ATP hydrolysis (Fig. 2 B and C),
suggesting that uncoupling is indeed driven by a protonophoric
or ionophoric mode of action. Similarly, a ΔpH gradient estab-
lished by the activity of cytochrome bo3, when reconstituted into
proteoliposomes (Fig. 2D), could be dissipated by BDQ (Fig.
2E). This is consistent with the lack of F1Fo-dependent effects in
IMVs (Fig. 1 B and C). Compared with the positive control
nigericin (Fig. 2F), 28-fold more BDQ was needed to achieve the
same degree of dissipation. In the F1Fo system, the rate of
requenching was maximal at 7.5 μM BDQ (Fig. 2C) and was 16-
fold lower than that of 10 μM nigericin. The presence of a Δψ
did not affect ATP hydrolysis inhibition (SI Appendix, Fig. S8) or
ΔpH dissipation in cytochrome bo3-containing proteoliposomes
(Fig. 2E). The lack of valinomycin dependency suggests an op-
posing Δψ was not a limiting factor. Although not necessarily as
Fig. 1. Uncoupling of E. coli IMVs by BDQ inhibits ATP synthesis. (A) Sche-
matic for reactions performed by IMVs: ATP hydrolysis establishes a proton
gradient, while ATP synthesis is energized by the proton gradient estab-
lished by NADH oxidation and subsequent electron transport chain activity.
(B) IMVs of E. coli C41 harboring an unc operon deletion (Δatp), or the same
strain overexpressing F1Fo (Δatp + F1Fo), were assessed for PMF establish-
ment using 250 nM acridine orange. Proton pumping was elicited by 200 μM
NADH and the proton gradient then dissipated by the indicated amounts of
BDQ. (C and D) IMVs of E. coli DK8 Δatp pBWU13 (F1Fo) were prepared and
measured as endpoint assays for (C) inhibition of ATP synthesis or (D) in-
hibition of ATP hydrolysis. (E) The structure of BDQ. DCCD was used at
100 μM. Error bars represent SD from three independent experiments. B and
C are kinetic traces representative of triplicate experiments.
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potent as nigericin, it is clear that BDQ at micromolar concen-
trations can collapse the ΔpH component of the PMF faster than
any E. coli proton-pumping enzyme can establish it. The ability
of BDQ to inhibit ATP synthesis in IMVs (Fig. 1) suggests this
activity is kinetically faster than physiological rates of combined
proton pumping by the respiratory chain.
BDQ Accumulates at Lipid Membranes to Collapse pH Gradients. We
prepared pyranine-containing phosphatidylcholine vesicles (lipo-
somes) to examine these effects in a more controlled system. This
technique quantifies the change in internal pH and is advantageous
due to the ability to artificially manipulate pH and cation gradients.
This method has previously been used to measure proton transport
in isolated E. coli Fo complexes (25) and internal pH changes in
protein-free liposomes (empty liposomes) (20). Empty liposomes
are advantageous, as we found they can maintain artificially
established gradients for far longer than Fo proteoliposomes (SI
Appendix, Fig. S9). We quantified the ability of BDQ to equilibrate
an artificially imposed ΔpH in the absence of any protein. Unlike
the prior model systems, this pH gradient is finite.
BDQ was able to equilibrate the intraliposomal (internal) pH
with the external (buffer) pH (Fig. 3B), regardless of whether the
external pH was acidic or alkaline. The internal volume of lipo-
somes containing the Fo subunit has previously been found to be
1.5–1.8 μL/mg lipid (25). The external buffer volume is therefore
likely to be at least 100-fold in excess for all experiments, so we
consider the external pH to be constant. Given sufficient time
and/or concentration of BDQ, it was possible to fully equilibrate
the internal pH with the external pH (SI Appendix, Fig. S9B). The
effective concentration for 50% of the equilibration response
(EC50) was 146 nM BDQ (Fig. 3C). In addition to equilibrating pH
gradients, BDQ could additionally alkalize the liposome interior by
∼0.5 pH units in the absence of a ΔpH (Fig. 3D). This was also
observed as an initial alkalization at external pH 6.53 (Fig. 3B). We
attribute this to intraliposomal accumulation of BDQ and sub-
sequent alkalization. Since BDQ is a weakly basic (pKa = 8.9) (11)
and highly lipophilic compound (logP = 7.13, logD = 5.42), it is
expected to partition into hydrophobic membranes and this result
is an experimental confirmation of this expectation. Aside from
this alkaline bias, BDQ mimics the pH equilibration profile of the
protonophore CCCP (Fig. 3D). These results show that BDQ has
the capacity to act as a cationic protonophore, consistent with the
suggestion of Feng et al. (11). However, this is inconsistent with the
lack of effects on the membrane potential in E. coli IMVs (SI
Appendix, Fig. S6) or M. smegmatis IMVs (13).
E. coli Fo Subunits Enhance BDQ-Elicited Proton Transport. We
compared Fo-containing and empty pyranine liposomes, initially
as a control to confirm the lack of F1Fo-dependent effects ob-
served previously (Figs. 1 and 2). In this system, membrane po-
tentials are manipulated to initiate proton transport through the
Fo subunit (Fig. 4 A and B) (25). Unexpectedly, BDQ appeared to
alleviate the requirement of valinomycin for inducing Fo-
dependent proton transport, when using a K+ diffusion potential
(Fig. 4C, K+out). This suggests that BDQ is able to shuttle K
+ ions
to create a Δψ using the starting gradient of KCl. Notably, BDQ
does not show the same biphasic kinetics as nigericin (Fig. 4 B and
C), although we cannot rule out that the timescale of the experi-
ment is too small to observe a second phase of BDQ activity.
Incorporation of Fo subunits enhanced the activity of BDQ,
alkalizing the interior by 0.44 pH units more than empty liposomes
after 90 s (Fig. 4C). A similar effect was observed when an inside
acidic ΔpH was used (Fig. 4D), but this could not be observed
when the salt gradients were reversed (Fig. 4C, K+in). Instead,
BDQ appeared to show a bias for alkalization, similar to the
empty liposome system (compare pH 6.53 in Fig. 3B). When an
Fig. 2. Uncoupling of proton-pumping proteoliposome systems by BDQ.
Schematics showing how proton pumping in proteoliposomal E. coli F1Fo (A)
or E. coli cytochrome bo3 (D) is achieved by either ATP hydrolysis or reduced
ubiquinone (QH2) addition, respectively. Unless otherwise indicated, 1 μM
valinomycin is added to counteract inhibitory membrane potentials. (B) F1Fo
proteoliposomes were incubated with ATP to establish a steady-state pH
gradient and then the indicated compounds were added to reverse acridine
orange quenching. (C) The initial rate of quenching reversal from B is
quantified as relative fluorescence units (RFU) min−1, error bars represent SD
from three independent experiments. Nig, 10 μM nigercin; VC, vehicle con-
trol. (E and F) Proton pumping in cytochrome bo3 proteoliposomes was
initiated by the addition of 2.5 μM UQ0 (Q0 in figure) to establish a steady-
state pH gradient, as determined by ACMA fluorescence quenching, in either
the presence or absence of 1 μM valinomycin. Either (E) BDQ or (F) nigericin
was added when indicated. Experiments are derived from kinetic traces.
Fig. 3. BDQ accumulates in pyranine-containing liposomes and collapses pH
gradients. (A) Schematic showing how the protonophore CCCP or the ion-
ophore nigericin can manipulate the internal pH in empty liposome systems,
depending on the type of imposed artificial gradient. (B) Suspensions of li-
posomes (internal pH ∼ 7.1) were incubated in buffers of the indicated pH
and treated with BDQ, with stirring in a fluorimeter. The experiment is a
kinetic trace representative of a technical triplicate. Subsequent experiments
are treated analogously to B, but as endpoint assays performed in a plate
reader (without stirring). (C) An initial pH gradient of ∼0.3 units (inside
acidic) was established and the indicated amounts of BDQ added. The EC50 is
indicated. (D) A total of 1 μM CCCP or BDQ was used as indicated and the
internal pH after 30-min treatment was measured. Experiments used a 2-mM
Mes-Mops-Tris buffer system (pH indicated). In C and D error bars indicate SD
from triplicate measurements, although they are not visible in D.








inside alkaline ΔpH was used (Fig. 4E), BDQ caused an initial
alkalization of Fo-containing liposomes. This is despite the fact
that the gradient used favors intraliposomal acidification (com-
pare pH 6.02 in Fig. 3B). The EC50 for this effect was 647 nM (Fig.
4E). This suggests that the E. coli Fo subunit, despite the lack of
mycobacterial BDQ binding site (8), has enhanced the ionophoric
activity of BDQ. We were unable to outcompete this effect with
DCCD, suggesting the binding site is not necessarily at the c-ring’s
proton-binding site.
BDQ Functions as a Proton/Monovalent-Cation Ionophore. We ob-
served that BDQ could alleviate the requirement of valinomycin in
Fo proton transport assays (Fig. 4C), suggesting it could move K
+ to
generate a Δψ. Given that BDQ can also move H+ (Fig. 3), we
hypothesized that BDQ functions as a H+/K+ exchanger. We used
empty liposomes to test this hypothesis, to remove the contribution
of Fo to intraliposomal pH change. Given the biphasic kinetics
possible with multisalt systems (Fig. 4B), only a single type of salt
was used for each experiment. Nigericin, a common H+/K+ anti-
porter, can convert a KCl gradient into a ΔpH gradient (15) and
this was readily achievable in our experimental system (Fig. 5A).
Nigericin caused either intraliposomal acidification or alkalization
depending on whether a higher concentration of salt was inside the
liposome or in the external buffer (Fig. 5A). BDQ could achieve a
similar effect (Fig. 5A). A high-inside KCl gradient was sufficient
for BDQ to cause intraliposomal acidification (Fig. 5A), despite
BDQ’s alkaline bias, but BDQ could elicit a 4.3-fold greater change
in liposomal pH for a high-outside KCl gradient. This agrees with
the directional bias observed in the Fo-liposome system (Fig. 4).
The response did not appear to be specific to K+, as LiCl and NaCl
were able to achieve the same effect (Fig. 5B and SI Appendix, Fig.
S10). It is possible that contaminating ions in soybean phosphati-
dylcholine (26) facilitates proton movement in the absence of added
salt (i.e., in the conditions of Fig. 3). Changing the buffer used or
the lipid used did not affect the result (SI Appendix, Fig. S11).
It is unlikely that Cl− ions are moved by BDQ, as this anion would
preferentially move in the same (symport) direction of the H+ ion to
prevent inhibitory counter potentials. In support of this, BDQ was
able to collapse a ΔpH established by cytochrome bo3 when either
potassium or sodium salts were used (SI Appendix, Fig. S12). This
occurred with a slightly lower magnitude and a secondary slower rate
when Na2SO4 was used, which is likely due to the stronger binding of
Na+ to SO4
− ion (the KD for dissociating Na
+ from NaSO4
− is less
than Na2SO4) (27). Movement of SO4
2− would require dissociation
of both Na+ ions first, a chemically unlikely phenomena under bi-
ological conditions, and this would not be consistent with a slower
secondary rate. As K+ is biologically accumulated at the cytoplasmic
face of the membrane, opposing the ΔpH, we continued to focus
characterization on this particular cation.
BDQ Does Not Transport K+ as a Salt. Nigericin transports K+ by
forming a salt with the carboxylate group (15). The ionization
state of nigericin therefore influences its K+ transport ability and
so sufficient acidity should compete with the binding of K+. To
test whether BDQ transports K+ similarly, we examined the
ionization-state dependence of both BDQ and nigericin. Being a
weak base (pKa ∼ 8.9), the unprotonated form of the drug only
appreciably exists at alkaline pH (SI Appendix, Fig. S13A). If the
amine groups coordinate K+, then increasing acidity should
Fig. 4. The E. coli Fo subunit enhances the activity of BDQ in proteoliposomes.
(A) Schematic showing how proton transport is routinely initiated in Fo pro-
teoliposomes, by either accumulating or depleting K+ to manipulate the
membrane potential in these preparations. (B) Salt gradients were established





in, respectively) into a 1-mL buffer containing 50mMNa2SO4 or




out, respectively). The change in internal pH was
measured. K+ is moved to generate a membrane potential as indicated in A.
Valinomycin or nigericin (100 nM each) was added when indicated. Nigericin
was additionally added to valinomycin experiments where indicated. (C) The
same experiment as B was performed, with the salt compositions as indicated,
except 1.5 μM BDQ was added at the arrow to either Fo-containing or empty
liposomes as indicated. (D and E) pH gradients were established in either (D) ATP
synthesis (inside acidic) or (E) ATP hydrolysis (inside alkaline) directions by di-
luting 5 μL of the indicated liposomes (∼pH 7.1 inside) into 1 mL of buffer either
1 unit more acidic or alkaline. The indicated amount of BDQ was added at the
arrow. In E, the initial rapid alkalization is quantified below the trace. Experi-
ments are representative of a technical triplicate and derived from kinetic traces.
Fig. 5. BDQ is a H+/K+ ionophore. (A) Liposomes were prepared in either 10mM
KCl or 100 mM KCl buffer and diluted in the opposite buffer to give a K+out:K
+
in
ratio of 10:1 or 1:10, respectively. The ratio in the key refers to the K+out:K
+
in
ratio. The indicated amount of BDQ was added and the 30-min endpoint was
recorded. U, untreated control. (B) LiCl, NaCl, and KCl were compared for their
ability to elicit proton movement upon BDQ addition. The 30-min endpoint was
recorded. Saltout:saltin refers to the concentration of the indicated salt (where 1:1
is 10 mM inside and outside) Data are relative to a saltout:saltin ratio of 1:1. (C and
D) In each experiment, a 10:1 K+out:K
+
in gradient is established, while the starting
pH is the same across the liposome. (C) The rate of pH change caused by 10−5 M
BDQ at different buffer pH values. (D) The rate of pH change caused by 10−9 M
Nig at different buffer pH values. D and E are derived from kinetic traces from
the multiwell-style experiment (Materials and Methods). Error bars indicate SD
from triplicate experiments. (E) Model for how BDQ functions as an ionophore
(Top) and how this might be localized at the site of a high-affinity binding
partner. Purple shading represents intensity of uncoupling.
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outcompete this binding. Instead, we find that the ability of BDQ
to elicit H+ movement, using solely a KCl gradient, is best at pH
7.5 and worse at either alkaline or acidic pH (Fig. 5C and SI Ap-
pendix, Fig. S13B). In comparison, more acidic pH values inhibited
the ability of nigericin to convert a KCl gradient into a ΔpH,
consistent with the formation of carboxylate salts (Fig. 5D and SI
Appendix, Fig. S13B). This suggests that, unlike nigericin, BDQ
does not transport K+ as a salt. We propose that BDQ chelates K+
through a pH-sensitive mechanism, distinct to the amine pro-
tonation site. Overall, these data suggest that BDQ can function as
a H+/K+ ionophore under the pH and salt conditions that emulate
a standard neutrophilic bacterium, like E. coli or M. tuberculosis,
and that this activity is enhanced at the location of a BDQ
binding partner.
Discussion
Researchers place emphasis on characterizing the primary tar-
gets of lead therapeutics, yet this risks overlooking potentially
meaningful and potentially bactericidal secondary effects. In this
work we report that BDQ has the ability to act as a H+/K+
ionophore. This can result in inhibition of ATP synthesis in
E. coli inverted membrane vesicles, despite its having no mea-
surable sensitivity to BDQ at a whole cell level. Here, we will
propose that target-dependent localization of BDQ enables
specific and potent uncoupling, despite the ionophoric nature of
its uncoupling mechanism.
BDQ is a lipophilic weak base (pKa = 8.9, logP = 7.13), so its
ability to move protons is likely similar to the well-described
weak acid CCCP and lipophilic weak bases such as ellipticine
(15, 18), where the charge from its ionization is delocalized
across π-orbitals. This would allow protonated BDQ to cross the
plasma membrane and equilibrate pH gradients. In contrast,
BDQ does not appear to bind K+ at the protonable amine
groups. This is unlike nigericin, which binds K+ as a carboxylic
salt (15), suggesting BDQ chelates K+ in a different manner. The
apparent pH optimum of 7.5 for BDQ converting a KCl gradient
into a pH gradient supports BDQ physiologically creating a futile
cycle of K+ and H+ in a neutrophilic bacterial cell, like M. tu-
berculosis: BDQ acquires a proton from the acidic periplasm and
moves to the neutral cytoplasm where the proton is displaced by
K+, before returning to the periplasm and so on (Fig. 5E, Top).
K+, being the predominant intracellular monovalent cation (28),
is likely to be more physiologically relevant than Na+ and Li+.
Previously, a direct interaction of BDQ and the F1Fo of M.
smegmatis was invoked, and subsequent disruption of the a–c
subunit interface was proposed to allow uncontrolled proton
influx (13). It has also been proposed that the basis of BDQ’s
uncoupling is purely chemical (11). We invoke a revised mech-
anism to reconcile the combined data. It is appropriate to ex-
trapolate our results to mycobacteria as the concentrations of
BDQ required to kill M. tuberculosis are far in excess of its MIC
and well within the effective concentrations used in this study
(30× and 300× MIC or 1.6 μM and 16 μM, respectively; ref. 12).
We note that purely chemical mechanisms are indeed possible in
mycobacteria: the AtpED32V mutant in our previous study still
had measurable pH gradient dissipation, albeit at a slower rate
and requiring higher concentrations (14.4 μM and 7.2 μM) of
BDQ (13). This strain is resistant to BDQ, so it is clear that
this chemical effect alone is insufficient for cell killing. The re-
cently published structure of the c-ring from Mycobacterium phlei
with bound BDQ suggests that BDQ cannot bind to ATP syn-
thase of nonmycobacterial species (8). However, BDQ appeared
to accumulate with greater efficacy at liposome preparations
containing the E. coli Fo subunit. The implications are twofold:
(i) there may be a lower affinity, although not necessarily spe-
cific, BDQ-binding site in the E. coli Fo subunit; and (ii) binding
BDQ may be necessary to localize its uncoupling activity to
physiologically relevant locations in a cell.
To address the first implication, BDQ is an arginine mimetic (8)
and may well have several lower affinity sites in the E. coli Fo
subunit, for example at other glutamate or aspartate residues.
Alternate binding sites are not without precedent, as Trp-16 of the
M. tuberculosis epsilon subunit has been suggested to be a second
BDQ-binding site (29, 30). To consider the second implication, we
will use BDQ binding to the target mycobacterial Fo as an ex-
ample. BDQ can bind and occupy all c subunits in the mycobac-
terial enzyme (8). However, binding interactions are inherently
transient: the dissociation constants for BDQ binding to the my-
cobacterial F1Fo c subunit have been determined to be 1.5–
19.7 μM, depending on the ionic strength of the buffer used (31).
As one molecule is released, another may diffuse into the binding
site. Continued on and off in this manner may localize BDQ at this
binding site. Furthermore, the dependency of the dissociation
constant on ionic strength (31) may be explained by BDQ binding
cations. It is conceivable that K+ actively competes for BDQ, re-
moving it from the a–c interface so that it can collapse the pH
gradient. In this model, the microenvironment around the target
protein would then be susceptible to uncoupling, while other areas
in the membrane will be unaffected (Fig. 5E). A dependency on
target-based localization allows for a stereospecific and target-
specific uncoupling, even if the nature of the uncoupling is iono-
phoric and likely present in the other stereoisomers of BDQ.
The lack of apparent selectivity between Li+, Na+, and K+
suggests BDQ does not form a size-gated polar core like vali-
nomycin (15). Ionophores with much broader ion specificities do
exist, such as lasalocid A (32), but parallels are not readily
drawn, owing to highly different chemical structures. Ellipticine,
a cationic protonophore, has previously been reported to be
most active around its pKa (18). In this work, BDQ was found to
be most active at pH values around 1.0 units more acidic than its
predicted pKa of 8.9 (11). It may be that the binding of salt and
interactions with the lipid membrane result in a lower than
predicted pKa. There is a possibility that several BDQ molecules
may act to coordinate a single cation, which may explain the
apparent lack of a singular cation-binding chemical motif and the
ability of BDQ to act protonophorically: BDQ may transport
protons as monomers and associate into multimers that complex
K+, depending on the particular conditions.
While BDQ may well have weak uncoupling activity in other
bacteria or mitochondria, our mechanism would suggest that it is
not biologically relevant without a protein target. BDQ has no
significant effect on oxygen consumption (10) and the membrane
potential (11) of mammalian mitochondria. A small effect (∼35%
inhibition at 200 μM) of BDQ on ATP synthesis has previously
been observed in mitochondria (10) and may represent this weak
uncoupling activity. However, BDQ has been found to have
no effect on the oxygen consumption of intact HepG2 and
RAW264.7 cell lines (14). The restricted antibacterial spectrum of
BDQ is well known (2) and uncoupling may well be overcome by
fermentation in other bacteria. BDQ may have arisen from a
plethora of favorable conditions in mycobacteria: a high-affinity
binding site for BDQ (8), a sensitivity to ionophores like nigericin
and valinomycin (33), and its dependence on respiration due to
the essentiality of F1Fo (22). Should uncouplers be targeted to
high affinity protein-binding sites in other organisms, the result
may well be a relevant therapeutic.
Oxidative phosphorylation is a very promising avenue for drug
development and so it is important that there is sufficient
knowledge of our current inhibitors, to allow well-informed de-
cisions for future lead compounds. Our proposal is that beda-
quiline is an atypical ionophore and that this ionophoric action
explains killing of mycobacteria by bedaquiline (as suggested in
ref. 13). This improves our understanding of the first-in-class
antibiotic and highlights that ionophores and protonophores,
typically associated with human toxicity (such as the case of di-
nitrophenol) (34), may well be rationally designed for potency








and specificity. Designing high-affinity membrane protein in-
hibitors in this way may be a more effective strategy than teth-
ering compounds to membrane-targeted compounds like TPP+
or plastoquinone (20, 35). These results also highlight the need
to further understand the role of potassium ions in the mecha-
nisms of new drug candidates. Finally, our work suggests new
respiratory inhibitors must be considered in the context of entire
respiratory chains and the PMF that intrinsically connects them.
Materials and Methods
Bacterial strains, media and growth conditions, sample preparation (inverted
membrane vesicles, F1Fo proteoliposomes, cytochrome bo3 proteoliposomes,
Fo-containing and empty pyranine liposomes), determination of cell growth
inhibition, and analytical methods are described in SI Appendix.
ATP Synthesis and Hydrolysis Assays. For endpoint measurements in IMVs, ATP
synthesis was measured using the hexokinase/glucose-6-phosphate de-
hydrogenase assay as previously described (10) and ATP hydrolysis was
measured using the spectrophotometric Pi release assay as previously de-
scribed (36). Real-time ATP synthesis measurments were made in an Oro-
boros O2k fluorespirometer, a clark-type oxygen electrode, modified to
simultaneously measure ATP by the previously described luciferase assay
(37). Further details are available in SI Appendix. F1Fo-proteoliposome sam-
ples were not preincubated with BDQ for ATP hydrolysis experiments and
measured using the spectrophotometric ATP-regenerating assay as pre-
viously described (36). All assays were performed at 37 °C.
Fluorescence Quenching Dependent on ΔpH or Δψ. Fluorescence quenching of
the pH-responsive fluorophores 9-amino-6-chloro-2-methoxyacridine (ACMA)
(excitation: 430 nm, emission: 470 nm) or acridine orange (excitation: 493 nm,
emission: 530 nm) was performed essentially as previously described (13). The
following modifications were made: 0.2 mg·mL−1 (final concentration) IMVs or
5 μL·mL−1 F1Fo proteoliposomes were added NADH or ATP were used to
initiate quenching as indicated. Unless otherwise indicated the concentration
of acridine orange was 5 μM. Assays were performed at 37 °C. For cytochrome
bo3 (cbo3) proteoliposomes fluorescence quenching of the pH responsive flu-
orophore, ACMA, was measured and is described in SI Appendix. Fluorescence
quenching of the Δψ responsive fluorophore oxonol VI was performed as
previously described (13), except quenching was measured photometrically at
590–630 nm and NADH was simultaneously measured at 340 nm.
Internal pH Quantification by Pyranine Fluorescence. The internal pH of
pyranine-containing liposomes was determined as previously described (25),
liposomes at a concentration of 60 mg (dry weight)/mL (lipid:dye ratio = 30 mg
lipid/μmol pyranine) were 100-fold diluted in incorporation buffer with the
salt and pH values indicated in text. A calibration curve of fluorescence ratio to
pH was determined for each incorporation buffer, containing 20 nM pyranine,
at known pH values (SI Appendix, Fig. S1A and Table S1). The contributions of
trace external pyranine were removed according to the equations defined in
ref. 25. Preparations of Fo-containing liposomes routinely had 50–60% of the
liposomes with Fo inserted, as assessed by the ratio of proton transport ob-
served from a K+/valinomycin diffusion potential vs. that of the protonophore
CCCP (SI Appendix, Fig. S1B). We did not correct for this, to enable comparison
with empty liposome controls. Our preparations were sensitive to DCCD (SI
Appendix, Fig. S1C), confirming the fidelity (coupled activity) of our prepara-
tion. Kinetic traces were measured on a Varian Cary Eclipse fluorimeter with
continuous stirring. Other experiments, presented as endpoint measurements,
used a Varioskan Flash plate reader, although traces were routinely recorded
to verify experimental integrity. Assays were performed at 37 °C.
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